Ga-PSMA-11

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MetastasisMetastatic Neuroendocrine Prostate Cancer

62 competitors in Metastasis

#DrugCompanyPhaseTrials

1

Blenoxane

Bristol-Myers Squibb

Approved

12

Norvir

AbbVie

Approved

—3

Neoral

Novartis

Approved

—4

Lynparza

AstraZeneca

Approved

—5

Tukysa

Pfizer

Approved

—6

Verzenio

Eli Lilly

Approved

—7

Taxol

Teva

Approved

—8

Trexall

Jazz Pharmaceuticals

Approved

—9

Camptosar

Pfizer

Approved

—10

Zometa

Pfizer

Approved

—Show 44 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

68Ga-PSMA-11 PET in Patients With Prostate Cancer

Completed·UUniversity of Colorado, Denver·Phase 3·NCT05197257·39 enrolled

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Active, not recruiting·Novartis·Phase 2·NCT05658003·63 enrolled

Metastasis2 trials

Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Recruiting·—·Phase 1·NCT06462508·30 enrolled

Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Unknown status·—·Phase 1·NCT05955677·100 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting·Novartis·Phase 1·NCT06379217·31 enrolled

Unspecified1 trial

Study of Diagnostic Performance of [18F]CTT1057 in BCR

Completed·Novartis·Phase 3·NCT04838613·190 enrolled

Details

Drug Info

Related News